TrialBMC neurology2017

Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy.

David Adams et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.